HC Wainwright Brokers Raise Earnings Estimates for Inventiva

Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 EPS estimates for Inventiva in a note issued to investors on Tuesday, October 15th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of ($2.43) for the year, up from their previous estimate of ($3.22). HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Inventiva's current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Inventiva's FY2027 earnings at ($3.06) EPS and FY2028 earnings at $1.20 EPS.

Separately, Stifel Nicolaus dropped their price objective on Inventiva from $25.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, September 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $16.25.

Inventiva Stock Up 8.7 %

IVA traded up $0.21 on Friday, hitting $2.63. The company had a trading volume of 195,650 shares, compared to its average volume of 81,033. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.75. The company's fifty day moving average price is $2.16 and its 200 day moving average price is $2.79.

Institutional Trading of Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC acquired a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,490 shares of the company's stock, valued at approximately $38,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.